APA (7th ed.) Citation

J, O., A, B., X, M., MP, S., MS, W., & DS, R. (2026). Bruton's tyrosine kinase inhibitors: A new class of multiple sclerosis therapeutics. The Lancet. Neurology, 25(7), 673. https://doi.org/10.1016/S1474-4422(26)00141-9

Chicago Style (17th ed.) Citation

J, Oh, Bar-Or A, Montalban X, Sormani MP, Weber MS, and Reich DS. "Bruton's Tyrosine Kinase Inhibitors: A New Class of Multiple Sclerosis Therapeutics." The Lancet. Neurology 25, no. 7 (2026): 673. https://doi.org/10.1016/S1474-4422(26)00141-9.

MLA (9th ed.) Citation

J, Oh, et al. "Bruton's Tyrosine Kinase Inhibitors: A New Class of Multiple Sclerosis Therapeutics." The Lancet. Neurology, vol. 25, no. 7, 2026, p. 673, https://doi.org/10.1016/S1474-4422(26)00141-9.